View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 11, 2020

China authorises trials of first nasal spray vaccine against Covid-19

China has granted approval to conduct human clinical trials of the country's first nasal spray Covid-19 vaccine candidate developed by a team of researchers led by the University of Hong Kong.

China has granted approval to conduct human clinical trials of the country’s first nasal spray Covid-19 vaccine candidate developed by a team of researchers led by the University of Hong Kong .

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The Phase I trials, scheduled to launch in November this year, will enrol 100 participants, reported Global Times.

This nasal Covid-19 vaccine candidate is said to be the first of its kind to secure authorisation from the China National Medical Products Administration.

The University of Hong Kong developed the vaccine in alliance with Xiamen University , and Beijing Wantai Biological Pharmacy.

According to the researchers, the nasal spray vaccine is designed to trigger the natural infection pathway of respiratory viruses to activate the immune response.

It is expected that the vaccine could produce double protection against influenza and Covid-19, if it also consists of influenza viruses, including H1N1, H3N2 and B.

The clinical trials of the vaccine candidate are expected to take at least one year to complete.

A nasal spray vaccination is expected to be easier to administer, as well as mass-produce and distribute as it leverages the mature influenza vaccine production technology.

The vaccine candidate uses live attenuated influenza vaccine and may not cause systemic side effects. It may lead to side effects in the respiratory system such as asthma and shortness of breath.

Researchers are not expecting side effects except for minor nasal obstruction or rhinorrhea.

However, further research is required to assess if immunity generated from nasal spray vaccinations will last longer compared to injected vaccines.

China has approved three Covid-19 vaccine candidates for clinical trials. It has also authorised emergency use of certain Covid-19 vaccines by domestic companies.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena